On August 12, JD-SW fell 3.08% in regular trading, trading at 122.5 HKD/share, with turnover of 2.69 billion HKD. The decline was driven by overnight weakness in US-listed Chinese equities and cautious sentiment ahead of the company's earnings release.

Overnight, JD's US-listed shares fell over 4%, while the Nasdaq Golden Dragon China Index dropped more than 2.5%, with broad selling pressure in Chinese assets transmitting to Hong Kong markets. Additionally, JD is scheduled to release its second-quarter and interim results on August 13. Market consensus expects quarterly revenue of approximately 345.6 billion RMB, representing year-over-year growth of 2.95% — a notable deceleration from the prior quarter's 4.85% growth. Earnings per share are expected to decline 0.59% year-over-year, prompting investors to adopt a wait-and-see stance.

Within the Internet and Direct Marketing Retail sector, the overall sector traded lower. Among individual stocks, BABA-W down 3.32%, MEITUAN-W down 1.88%, ALI HEALTH down 1.91%, JD HEALTH down 1.12%, PA GOODDOCTOR down 1.23%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)